What BMI do you need for Zepbound under Horizon BCBS?

For weight loss on Employer / Commercial Insurance plans, Horizon BCBS requires a BMI of 35 or higher.

How long does a Zepbound approval last with Horizon BCBS?

Initial approvals last 3 months, and renewals are granted in 6-month periods.

What does Horizon BCBS require to renew Zepbound?

At least 5% weight loss from the starting weight and Adult: weight loss >= 5% from baseline OR weight loss >= 1 lb/week from baseline; AND baseline BMI >= 35 and current BMI >= 35 (measured within last 30 days). Failed efficacy precludes future coverage of same drug. Obesity benefit restriction and T2DM exclusion are re-verified at renewal. BMI must be obtained during in-office visit within last 30 days. Continued active participation in weight management program required. Note: no pediatric (12-17) pathway specified for Zepbound in the criteria.

What if my plan excludes weight loss medications?

Horizon BCBS has separate Zepbound policies for osa, which are covered on some plan types and don't depend on the weight-loss benefit. Zepbound is also available for cash through LillyDirect.

How current is this information?

This page reflects Horizon BCBS's written policy as of its current version, last verified against the source document on June 5, 2026.

Horizon BCBS

Does Horizon BCBS cover Zepbound?

Quick answer · Weight Loss

Horizon BCBS covers it only when the plan's benefit includes it on Employer / Commercial Insurance.

Employer / Commercial Insurance: Depends on your plan's benefit. Obesity must NOT be restricted from coverage under the patient's benefit

Last verified June 5, 2026. Source: glp1-for-non-diabetic-use.pdf. How we verify this data →

Check your card for your exact plan →

Zepbound for Weight Loss

What Horizon BCBS requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Depends on your plan's benefit

Obesity must NOT be restricted from coverage under the patient's benefit

What you need to qualify

BMI of 35 or higher
6 months of a documented diet and exercise program
Prior trial of another GLP-1 medication (liraglutide (Saxenda)) for at least 90 days
Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

Adult weight management (Zepbound)

All of:

Obesity is NOT restricted from coverage under the patient's benefit
Patient does NOT have Type 2 diabetes
Patient is new to therapy, new to Prime, or attempting a repeat weight loss course of therapy
Patient is an adult (> 18 years of age)
BMI >= 35 kg/m2 with at least one comorbidity (e.g., hypertension, OSA, CVD, dyslipidemia)
Weight loss regimen of low-calorie diet, increased physical activity, and behavioral modifications for minimum 6 months (documentation required within last 6 months)
Baseline weight and BMI obtained during in-office visit within last 30 days
Active participation in in-person, digital, or telehealth weight management program
Patient starting therapy OR has achieved and maintained weight loss >= 5% from baseline
Will NOT use in combination with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical)
Will NOT use in combination with another GLP-1 receptor agonist
No FDA labeled contraindications to requested agent
Currently on low-calorie diet, increased physical activity, and behavioral modifications

Plus any one of:

Patient has NOT tried a targeted weight loss agent (e.g., Saxenda, Wegovy, Zepbound) in the past 12 months
Patient has tried a targeted weight loss agent in the past 12 months AND prescriber anticipates success with repeating therapy
Inadequate response to 3-month trial of liraglutide (Saxenda generic) not expected to occur with Zepbound
Intolerance or hypersensitivity to liraglutide (Saxenda generic) not expected to occur with Zepbound
FDA labeled contraindication to liraglutide (Saxenda generic) not expected to occur with Zepbound

Documentation to bring

Documentation that obesity is NOT restricted from coverage under patient's benefit
Documentation confirming patient does NOT have Type 2 diabetes
Baseline weight and BMI from in-office visit within the last 30 days
Documentation of active participation in lifestyle changes within last 6 months (e.g., food diary, exercise log, step counter report, gym attendance log, fitness tracker printout)
Medical records confirming active participation in in-person, digital, or telehealth weight management program
Medical records supporting prior liraglutide (Saxenda generic) trial (inadequate response, intolerance, or contraindication) OR documentation that patient has not tried a targeted weight loss agent in past 12 months OR documentation supporting repeat therapy with prescriber anticipation of success
MedWatch form if intolerance/hypersensitivity to liraglutide is the reason for step-through

Quantity limits

2.5mg — 4 vials or 4 pens per 180 days (84-day)
5mg, 7.5mg, 10mg, 12.5mg, 15mg — 4 vials or 4 pens per 28 days

Approval and renewal

Initial approval: 3 months
Renewal: every 6 months
To renew, the plan looks for at least 5% weight loss from the starting weight and Adult: weight loss >= 5% from baseline OR weight loss >= 1 lb/week from baseline; AND baseline BMI >= 35 and current BMI >= 35 (measured within last 30 days). Failed efficacy precludes future coverage of same drug. Obesity benefit restriction and T2DM exclusion are re-verified at renewal. BMI must be obtained during in-office visit within last 30 days. Continued active participation in weight management program required. Note: no pediatric (12-17) pathway specified for Zepbound in the criteria. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

Type 2 diabetes (T2DM patients excluded from weight_loss indication)
Concomitant use with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical)
Concomitant use with another GLP-1 receptor agonist
Any FDA labeled contraindications to the requested agent

Policy note: Zepbound 2.5mg has a quantity limit of 4 vials/pens per 180 days; all other strengths are 4 vials/pens per 28 days. Quantity limit criteria allow exceptions for Zepbound 2.5mg used for maintenance therapy if patient cannot use higher strength maintenance dose and has achieved weight loss on lower strength. Initial approval duration 3 months for obesity indication. Renewal approval is 6 months. Step-therapy requires prior liraglutide (Saxenda generic) trial or documented intolerance/contraindication. No pediatric pathway is explicitly described for Zepbound in the weight_loss criteria (unlike Saxenda and Wegovy). Adult-only weight_loss criteria implied by the qualification pathway.

verified June 5, 2026 · source: glp1-for-non-diabetic-use.pdf

Zepbound for Osa

What Horizon BCBS requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

BMI of 30 or higher
Diagnosed obstructive sleep apnea (AHI of 15 or higher)

Qualification pathways

You can qualify through any one of these.

OSA with obesity (Zepbound)

All of:

Diagnosis of obstructive sleep apnea (OSA) (medical records required)
Polysomnography (PSG) or home sleep apnea test performed (sleep study required)
AHI >= 15 events/hour from baseline (prior to initiation of pharmacotherapy) (sleep study required)
Requested agent is Zepbound
BMI >= 30 kg/m2 (medical records required)
Will NOT use in combination with another weight loss agent
Will NOT use in combination with another GLP-1 receptor agonist
No FDA labeled contraindications to requested agent
Currently on low-calorie diet, increased physical activity, and behavioral modifications

Documentation to bring

Medical records confirming diagnosis of obstructive sleep apnea (OSA)
Sleep study results (polysomnography or home sleep apnea test) showing AHI >= 15 events/hour at baseline
Medical records confirming BMI >= 30 kg/m2

Quantity limits

2.5mg — 4 vials or 4 pens per 180 days (84-day)
5mg, 7.5mg, 10mg, 12.5mg, 15mg — 4 vials or 4 pens per 28 days

Approval and renewal

Initial approval: 6 months
Renewal: every 6 months
To renew, the plan looks for Patient must have had clinical benefit with the requested agent (e.g., reduction in AHI, decrease in Epworth Sleepiness Scale). OSA diagnosis and AHI/BMI requirements are NOT re-verified at renewal — only clinical benefit confirmation is required.

Not covered when

Concomitant use with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical)
Concomitant use with another GLP-1 receptor agonist
Any FDA labeled contraindications to the requested agent

Policy note: PAP therapy trial is NOT required prior to approval — the policy does not mandate a prior PAP/CPAP trial. Both patients currently on PAP and those not on PAP are eligible (consistent with SURMOUNT-OSA trial design referenced in the document). AHI >= 15 events/hour corresponds to moderate-to-severe OSA. Initial approval is 6 months (non-obesity indication). Renewal is 6 months with clinical benefit required (reduction in AHI or decrease in Epworth Sleepiness Scale).

verified June 5, 2026 · source: glp1-for-non-diabetic-use.pdf

Why Zepbound requests get denied by Horizon BCBS

Based on what this policy asks for. Fix these before the first submission.

Your specific plan doesn't include the weight loss benefit. Coverage here is conditional on the benefit design (often an optional employer add-on), so confirm it before submitting.
Wrong brand for the diagnosis. Zepbound and Mounjaro are the same molecule with different approved uses; a request for Zepbound under a diagnosis that matches Mounjaro is routinely denied.
BMI not documented in the chart notes (or documented without a baseline weight and date).
No documented diet and exercise program.
Required prior medication trials not documented.
Baseline weight wasn't recorded at the start, so the required weight loss can't be shown at renewal.

If weight loss isn't covered on your plan

Horizon BCBS has separate Zepbound policies that don't depend on the weight loss benefit:

Osa — covered on Employer / Commercial Insurance.

Zepbound is also sold directly by Eli Lilly without insurance through LillyDirect.

Frequently asked questions

Does Horizon BCBS cover Zepbound?: Horizon BCBS covers it only when the plan's benefit includes it on Employer / Commercial Insurance.
What BMI do you need for Zepbound under Horizon BCBS?: For weight loss on Employer / Commercial Insurance plans, Horizon BCBS requires a BMI of 35 or higher.
How long does a Zepbound approval last with Horizon BCBS?: Initial approvals last 3 months, and renewals are granted in 6-month periods.
What does Horizon BCBS require to renew Zepbound?: At least 5% weight loss from the starting weight and Adult: weight loss >= 5% from baseline OR weight loss >= 1 lb/week from baseline; AND baseline BMI >= 35 and current BMI >= 35 (measured within last 30 days). Failed efficacy precludes future coverage of same drug. Obesity benefit restriction and T2DM exclusion are re-verified at renewal. BMI must be obtained during in-office visit within last 30 days. Continued active participation in weight management program required. Note: no pediatric (12-17) pathway specified for Zepbound in the criteria.
What if my plan excludes weight loss medications?: Horizon BCBS has separate Zepbound policies for osa, which are covered on some plan types and don't depend on the weight-loss benefit. Zepbound is also available for cash through LillyDirect.
How current is this information?: This page reflects Horizon BCBS's written policy as of its current version, last verified against the source document on June 5, 2026.

Other medications under Horizon BCBS

Zepbound coverage under other plans

All insurance plans · All medications

This page summarizes Horizon BCBS's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.